Search Result
Results for "
Val-Cit
" in MedChemExpress (MCE) Product Catalog:
7
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-100374
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
|
-
-
- HY-41189
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Val-Cit-PAB-PNP has superior plasma stability comparable to that of non-cleavable linkers .
|
-
-
- HY-145929
-
|
MC-Val-Cit-PAB-DX8951
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. MC-Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker.
|
-
-
- HY-12362
-
-
-
- HY-112786
-
|
Vc-MMAF
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity .
|
-
-
- HY-19318
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.
|
-
-
- HY-140014
-
|
|
ADC Linker
|
Cancer
|
|
Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-130989
-
|
NHS-Glutarate-Val-Cit-PAB-MMAE
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SuO-Glu-Val-Cit-PAB-MMAE (NHS-Glutarate-Val-Cit-PAB-MMAE) consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-153031
-
|
Val-Cit-PAB-DX8951
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker .
|
-
-
- HY-128904
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-duocarmycin chloride is a agent-linker conjugate for ADC with potent antitumor activity by using Duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.
|
-
-
- HY-W190927
-
|
MC-Val-Cit-PAB-Doxorubicin
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-Doxorubicin (MC-Val-Cit-PAB-Doxorubicin) is drug-linker conjugate for ADC. The maleimide can conjugate with thiol containing molecules. Doxorubicin is an anthracycline antibiotic with antineoplastic activity
|
-
-
- HY-148245
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
OH-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-128902
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-vinblastine is a agent-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
|
-
-
- HY-130937
-
|
|
ADC Linker
|
Cancer
|
|
DBCO-Val-Cit-PABC-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Val-Cit-PABC-PNP is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
-
- HY-130990
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
-
- HY-19811
-
-
-
- HY-141141
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Val-Cit-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-W038702
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Val-Cit-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-147286
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Ac-Lys-Val-Cit-PABC-MMAE is a agent-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .
|
-
-
- HY-100567
-
-
-
- HY-160441
-
-
-
- HY-19812
-
|
LCB14-0602
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a agent-linker conjugate for ADC. Acetylene-linker-Val-Cit-PABC-MMAE is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-172287
-
|
|
ADC Linker
|
Cancer
|
|
DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.
|
-
-
- HY-141860
-
|
|
PSMA
Microtubule/Tubulin
Reactive Oxygen Species (ROS)
Cytochrome P450
|
Cancer
|
|
PSMA-Val-Cit-PAB-MMAE is a small-molecule conjugate targeting PSMA, with Monomethyl auristatin E (MMAE) (HY-15162) as its cytotoxic payload. PSMA-Val-Cit-PAB-MMAE binds to PSMA, thereby being delivered into PSMA-expressing prostate cancer cells. Subsequently, the Val-Cit linker is cleaved under the mediation of cathepsin B, releasing active MMAE. PSMA-Val-Cit-PAB-MMAE inhibits CYP3A4 activity (IC50 = 11.2 μM), induces intracellular ROS production and oxidative stress, disrupts the cytoskeleton through microtubule destabilization, and induces prostate cancer cell death. PSMA-Val-Cit-PAB-MMAE can be used in research related to prostate cancer .
|
-
-
- HY-78736
-
|
|
ADC Linker
|
Cancer
|
|
Val-Cit-PAB-OSBT is a degradable ADC linker composed of the peptide Val-Cit-PAB and the OSBT group, which ensures stable performance during targeted drug delivery .
|
-
-
- HY-100566
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .
|
-
-
- HY-158137
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-PAB-DEA-Dxd (compound 81) is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (DNA topoisomerase I inhibitor). Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis .
|
-
-
- HY-W591408
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate, which can be used for the synthesis of ADC molecules. MMAE (HY-15162) is a tubulin inhibitor, which can be used as an ADC toxin. DBCO-Val-Cit-PAB is the linker with the electrophilic group .
|
-
-
- HY-19813A
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition [1] .
|
-
-
- HY-44177
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-PAB-MMAF sodium is a drug-Linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)
|
-
-
- HY-171931A
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
Aminocaproyl-Val-Cit-PABC-Exatecan TFA is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan TFA can be used for ADC molecues synthesis .
|
-
-
- HY-128711
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F) .
|
-
-
- HY-139726
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-PEG4-Val-Cit-PAB-MMAE is part of a drug-linker conjugate for ADC. Mal-PEG4-Val-Cit-PAB-MMAE contains a degradable ADC linker Mal-PEG4-Val-Cit-PAB (HY-126672) and a potent tubulin inhibitor MMAE (HY-15162) .
|
-
-
- HY-W190913
-
|
|
ADC Linker
|
Cancer
|
|
DBCO-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. PNP can be substituted by amine-containing payload. DBCO enable click chemistry with azide molecules.
|
-
-
- HY-153031A
-
|
Val-Cit-PAB-DX8951 TFA
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) TFA is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan TFA is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker .
|
-
-
- HY-177599
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Boc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC, which is composed of a linker Boc-Val-Cit-PAB (HY141141) and a Microtubule inhibitor MMAE (HY-15162). Boc-Val-Cit-PAB-MMAE can be used for ADC synthesis.
|
-
-
- HY-171931
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
Aminocaproyl-Val-Cit-PABC-Exatecan is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan can be used for ADC molecues synthesis .
|
-
-
- HY-78738G
-
|
|
ADC Linker
|
Cancer
|
|
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
-
-
- HY-128908
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-Indibulin is a agent-linker conjugate for ADC with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB.
|
-
-
- HY-160774
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
Val-Cit-PABC-DOX (compound 10109), an epsilon-poly-L-lysine-based drug conjugate, is an agent-linker conjugate for ADC by using a DNA topoisomerase I and topoisomerase II inhibitor, Doxorubicin (HY-15142), linked via the linker, Val-Cit-PABC .
|
-
-
- HY-177681
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Microtubule/Tubulin
|
Cancer
|
|
N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
|
-
-
- HY-101909
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-PAB-MMAF is a drug-Linker conjugate for ADC. Val-Cit-PAB-MMAF is composed of an ADC linker (peptide Val-Cit-PAB) and a potent microtubule polymerization inhibitor MMAF (HY-15579) .
|
-
-
- HY-128906
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-Retapamulin is a agent-linker conjugate for ADC with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
|
-
-
- HY-128903
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-carfilzomib iodide is a agent-linker conjugate for ADC with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
|
-
-
- HY-148326
-
|
|
ADC Linker
|
Others
|
|
Glu(OtBu)-Val-Cit-PAB-OH (compound L5-1c) is an non-cleavable ADC linker. Glu(OtBu)-Val-Cit-PAB-OH has been used to synthesis protein-tubulysin conjugates .
|
-
-
- HY-130936
-
|
|
ADC Linker
|
Cancer
|
|
DBCO-Val-Cit-PABC-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Val-Cit-PABC-OH is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
-
- HY-156897
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-amide-Ph-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs) .
|
-
-
- HY-141143
-
|
|
ADC Linker
|
Cancer
|
|
MC(C5)-Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-100374G
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
|
-
-
- HY-148871
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mc-Val-Cit-PAB-Gefitinib chloride is a agent-linker conjugates for ADC. Mc-Val-Cit-PAB-Gefitinib chloride consists of Gefitinib (HY-50895) (an EGFR tyrosine kinase inhibitor) and the ADC linker Mc-Val-Cit-PAB .
|
-
- HY-12362G
-
|
|
ADC Linker
|
Cancer
|
|
Val-cit-PAB-OH GMP is a GMP grade Val-cit-PAB-OH (HY-12362). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Val-cit-PAB-OH is a degradable ADC linker.
|
-
- HY-20336G
-
|
|
ADC Linker
|
Cancer
|
|
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-164303
-
-
- HY-128907
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-clindamycin is a agent-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-126532
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Fmoc-Val-Cit-PAB-Duocarmycin TM is a agent-linker conjugate for ADC by using the antitumor antibiotic, Duocarmycin TM, linked via Fmoc-Val-Cit-PAB.
|
-
- HY-128909
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-rifabutin is a agent-linker conjugate for ADC with potent antitumor activity by using rifabutin (an DNA-dependent RNA polymerase inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-130935
-
|
|
ADC Linker
|
Cancer
|
|
DBCO-Val-Cit-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Val-Cit-OH is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-128899
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-Auristatin E is a agent-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-19697
-
-
- HY-177146
-
|
MC-Val-Cit-PAB-Paclitaxel
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Paclitaxel-MVCP (MC-Val-Cit-PAB-Paclitaxel) is a MC-Val-Cit-PAB (HY-78738) and Paclitaxel (HY-B0015) conjugate, and can be used for synthesis of Paclitaxel-nucleolin aptamer conjugate .
|
-
- HY-158137A
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-PAB-DEA-Dxd (Compound 81) TFA is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (HY-13631D). Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis .
|
-
- HY-177685
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Microtubule/Tubulin
|
Cancer
|
|
N-(TCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(TCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
|
-
- HY-172291
-
|
|
ADC Linker
|
Cancer
|
|
Mal-amide-PEG8-Val-Cit-PAB-PNP is a cleavable ADC linker featuring a maleimide, a PEG spacer, a Val-Cit dipeptide, a PAB. and a PNP carbonate. Maleimide is a thiol-specific covalent linker which is used to label cysteine residues in proteins while the PNP group acts as a highly activated leaving group. Val-Cit linkers are cleaved by cytoplasmic peptidases.
|
-
- HY-78736G
-
|
|
ADC Linker
|
Cancer
|
|
Val-Cit-PAB-OSBT GMP is a GMP grade Val-Cit-PAB-OSBT (HY-78736). Val-Cit-PAB-OSBT is a degradable ADC linker, which is composed of the polypeptide Val-Cit-PAB and OSBT groups coupled together .
|
-
- HY-19318G
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.
|
-
- HY-171159
-
-
- HY-126671
-
|
|
ADC Linker
|
Cancer
|
|
Mal-Phe-C4-Val-Cit-PAB is a cleavable ADC linker containing a Maleimide group. Mal-Phe-C4-Val-Cit-PAB is used for making antibody-drug conjugate.
|
-
- HY-177687
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Microtubule/Tubulin
|
Cancer
|
|
N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
|
-
- HY-177682
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Microtubule/Tubulin
|
Cancer
|
|
N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
|
-
- HY-177686
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Microtubule/Tubulin
|
Cancer
|
|
N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
|
-
- HY-177683
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Microtubule/Tubulin
|
Cancer
|
|
N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
|
-
- HY-177688
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Microtubule/Tubulin
|
Cancer
|
|
N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
|
-
- HY-158135
-
|
|
ADC Linker
|
Cancer
|
|
Val-Cit-PAB-DEA-COOH (compound 17) is an ADC linker that can be used in the synthesis of ADCs .
|
-
- HY-W800837
-
|
|
ADC Linker
|
Cancer
|
|
t-Boc-N-amido-PEG4-Val-Cit is a protease-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit dipeptide. The Val-Cit dipeptide is cleavable by cell proteases and features a carboxylic acid which is free for coupling reactions with amines to form amides. The Boc can be removed under acidic conditions to reveal a free primary amine, which may be used in a variety of reactions such as coupling or reductive amination.
|
-
- HY-152919
-
|
|
ADC Linker
|
Cancer
|
|
Mal-amide-PEG8-Val-Cit-PAB-OH is a cleavable ADC linker featuring a maleimide, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB functional group. Maleimide is used to covalently bind free thiols on the cysteine residues of proteins. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery with the help of the PAB structure.
|
-
- HY-W800617
-
|
|
ADC Linker
|
Cancer
|
|
NH2-PEG1-Val-Cit-PAB-OH is a cleavable ADC linker intermediate featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
|
-
- HY-W800619
-
|
|
ADC Linker
|
Others
|
|
NH2-PEG4-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
|
-
- HY-W800618
-
|
|
ADC Linker
|
Others
|
|
NH2-PEG3-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
|
-
- HY-W800620
-
|
|
ADC Linker
|
Others
|
|
NH2-PEG6-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
|
-
- HY-W800814
-
|
|
ADC Linker
|
Cancer
|
|
Azido-PEG8-Amido-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome, the ADC payload will be released only in the cell. Azido will react with DBCO, BCN or other alkyne groups through click chemistry. PEG spacer increases aqueous solubility. Reagent grade, for research purpose.
|
-
- HY-177548
-
-
- HY-160756A
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-Exatecan TFA is an agent-linker conjugate for ADC. Val-Cit-Exatecan TFA is composed of a DNA topoisomerase I Exatecan (HY-13631) and a cathepsin cleavable ADC linker .
|
-
- HY-147286A
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Ac-Lys-Val-Cit-PABC-MMAE (formic) is a agent-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitorMonomethyl auristatin E (HY-15162) .
|
-
- HY-147021A
-
-
- HY-164273
-
-
- HY-164275
-
-
- HY-W591286
-
-
- HY-126667
-
|
|
ADC Linker
|
Cancer
|
|
SC-Val-Cit-PAB is a cleavable ADC linker for antibody-drug conjugates (ADCs).
|
-
- HY-153236
-
-
- HY-19318B
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-D-Val-Cit-PAB is a cleavable linker for antibody-agent-conjugation (ADC) .
|
-
- HY-177679
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Microtubule/Tubulin
|
Cancer
|
|
N-(Amino-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Amino-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
|
-
- HY-177678
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Microtubule/Tubulin
|
Cancer
|
|
N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
|
-
- HY-156727
-
|
|
ADC Linker
|
Cancer
|
|
Val-Cit-PABC-Ahx-May is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-156727A
-
|
|
ADC Linker
|
Cancer
|
|
Val-Cit-PABC-Ahx-May TFA is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-156896
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-amide-Cbz-N(Me)-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs) .
|
-
- HY-186185
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Others
|
|
OSu-Val-Cit-PAB-Exa (compound D) is a cleavable linker-payload conjugate (usable for ADC synthesis). OSu-Val-Cit-PAB-Exa bears an N-terminal N-hydroxysuccinimide (OSu) ester group, and comprises Val-Cit, p-aminobenzyl alcohol (PAB) and Exatecan (HY-13631). OSu-Val-Cit-PAB-Exa serves as a payload-linker intermediate for polypeptide conjugation .
|
-
- HY-142079
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE (compound 62) is a drug-linker conjugate that contains a monomethyl auristatin E (MMAE) drug moiety, which is linked to a bromoacetamide-containing extension unit via a valine-citrulline (Val-Cit) dipeptide and a self-immolative p-aminobenzyl (PAB) spacer. Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE is applicable to the research of breast cancer, anaplastic large cell lymphoma and lung adenocarcinoma .
|
-
- HY-160756
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
Val-Cit-Exatecan is a peptide-linked anti-tumor payload that can be used for the synthesis of antibody-drug conjugates (ADC). Val-Cit-Exatecan consists of DNA TopI inhibitor Exatecan (HY-13631) and a cathepsin-cleavable ADC linker (valine-citrulline). Val-Cit-Exatecan can be used in the research of colorectal cancer, gastric cancer, breast cancer, non-small cell lung cancer, ovarian cancer, head and neck cancer, pancreatic cancer, cervical cancer, and melanoma .
|
-
- HY-181992
-
|
|
Drug-Linker Conjugates for ADC
|
Inflammation/Immunology
Cancer
|
|
Mal-PEG4-Val-Cit-PAB-MSA-2 is a Drug-Linker Conjugates for ADC. Mal-PEG4-Val-Cit-PAB-MSA-2 consists of the ADC Cytotoxin MSA-2 (HY-136927) and a linker Mal-PEG4-Val-Cit-PAB-OH (HY-140143). Mal-PEG4-Val-Cit-PAB-MSA-2 can be used for synthesis of ADCs .
|
-
- HY-177680
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Microtubule/Tubulin
|
Cancer
|
|
N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
|
-
- HY-148875
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Py-MAA-Val-Cit-PAB-MMAE is a drug-Linker conjugates for ADC, which is composed of MMAE (HY-15162) and Py-MAA-Val-Cit-PAB linked. Py-MAA-Val-Cit-PAB-MMAE can be used to synthesize Zapadcine-3a, which targeting TRAILR2. Zapadcine-3a has broad-spectrum anti-tumor activity, and can specifically kill TRAILR2-positive tumors .
|
-
- HY-164310
-
|
|
Microtubule/Tubulin
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TCO-PEG3-Glu-Val-Cit-PABC-MMAF is a linker-drug conjugate, which is consisted of a click pair TCO, a spacer PEG, a cleavable linker Glu-Val-Cit, a PBAC group and a cytotoxin MMAF (HY-15579). TCO-PEG3-Glu-Val-Cit-PABC-MMAF can be used for synthesis of dual drug ADC .
|
-
- HY-W800626
-
|
|
ADC Linker
|
Cancer
|
|
Boc-PEG6-Val-Cit-PAB-OH is an ADC linker that can be used for synthesizing antibody-drug conjugates (ADC). Boc-PEG6-Val-Cit-PAB-OH can be used for cancer research .
|
-
- HY-128905
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-dimethylDNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus.
|
-
- HY-177684
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Microtubule/Tubulin
|
Cancer
|
|
N-(endo-BCN-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(endo-BCN-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
|
-
- HY-141144
-
|
|
ADC Linker
|
Cancer
|
|
OPSS-Val-Cit-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-126670
-
|
|
ADC Linker
|
Cancer
|
|
mDPR(Boc)-Val-Cit-PAB is a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC) .
|
-
- HY-141142
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-130930
-
|
|
ADC Linker
|
Cancer
|
|
Acid-propionylamino-Val-Cit-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-141145
-
|
|
ADC Linker
|
Cancer
|
|
OPSS-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-156758
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-PEG8-Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Mal-PEG8-Val-Cit-PAB-MMAF contains a cleavable ADC linker and a potent tubulin inhibitor MMAE (HY-15162) .
|
-
- HY-141156
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-PEG8-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Mal-PEG8-Val-Cit-PAB-MMAE contains a cleavable ADC linker and a potent tubulin inhibitor MMAE (HY-15162) .
|
-
- HY-153263
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
(Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC .
|
-
- HY-W800625
-
|
|
ADC Linker
|
Cancer
|
|
Boc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
|
-
- HY-W800623
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-PEG6-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
|
-
- HY-W800621
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine for use in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
|
-
- HY-W800624
-
|
|
ADC Linker
|
Cancer
|
|
Boc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
|
-
- HY-W800622
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
|
-
- HY-126674
-
|
|
ADC Linker
|
Cancer
|
|
Mal-Phe-C4-Val-Cit-PAB-DMEA is a cleavable ADC linker containing a Maleimide group. Mal-Phe-C4-Val-Cit-PAB-DMEA is used for making antibody-drug conjugate.
|
-
- HY-112099
-
|
|
ADC Linker
|
Cancer
|
|
Mc-Val-Cit-PAB-Cl is a cleavable ADC linker. Mc-Val-Cit-PAB-Cl can be used to conjugate MMAE and antibody to form antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE with IC50s of 3.3 and 0.95 nM for BJAB and WSU cell lines in cytotoxicity assay).
|
-
- HY-130222
-
|
|
ADC Linker
PROTAC Linkers
|
Cancer
|
|
Mal-PEG2-Val-Cit-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG2-Val-Cit-PAB-OH also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-126672
-
|
|
ADC Linker
|
Cancer
|
|
Mal-amide-PEG4-Val-Cit-PAB-OH is a cleavable ADC linker containing a Maleimide group. Mal-amide-PEG4-Val-Cit-PAB-OH is used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-126676
-
|
|
ADC Linker
PROTAC Linkers
|
Cancer
|
|
DBCO-(PEG2-Val-Cit-PAB)2 is a dual cleavable ADC linker for antibody-drug conjugates (ADCs). DBCO-(PEG2-Val-Cit-PAB)2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. DBCO-(PEG2-Val-Cit-PAB)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-164346
-
|
|
Microtubule/Tubulin
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Amine-PEG8-Val-Cit-PAB-MMAE is a potent drug-linker conjugate for antibody-drug conjugates (ADCs).Amine-PEG8-Val-Cit-PAB-MMAE consists of the linker amine-PEG8-Vali-Cit-PAB and the payload MMAE (HY-15162), and can be used to synthesize ADCs. Amine-PEG8-Val-Cit-PAB-MMAE can be used for the research of gastric cancer, colon cancer, lung adenocarcinoma .
|
-
- HY-139642
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB .
|
-
- HY-130922
-
|
|
ADC Linker
|
Cancer
|
|
BCN-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . BCN-PEG1-Val-Cit-OH is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-126533
-
|
|
ADC Linker
|
Cancer
|
|
PDP-C1-Ph-Val-Cit is a cleavable ADC linker used for antibody-drug conjugates (ADCs).
|
-
- HY-130934
-
|
|
ADC Linker
|
Cancer
|
|
TCO-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . TCO-PEG1-Val-Cit-OH is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
|
-
- HY-164380
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-Val-Cit-Gly-exatecan-β-D-glucopyranosiduronic acid (example 13) is a drug-linker conjugate that consists of a DNA topoisomerase I inhibitor Exatecan (HY-13631) and a linker (HY-180841). MC-Val-Cit-Gly-exatecan-β-D-glucopyranosiduronic acid can be used in synthesis of ADC .
|
-
- HY-78738
-
|
|
ADC Linker
|
Cancer
|
|
MC-Val-Cit-PAB is a cleavable ADC Linker that forms part of VcMMAE (HY-15575). VcMMAE is Drug-Linker Conjugates for ADCs. The ADC Cytotoxin in VcMMAE is MMAE, a tubulin polymerization inhibitor.
|
-
- HY-145489
-
|
|
ADC Linker
|
Cancer
|
|
Mal-PEG2-Val-Cit-PABA is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-136106
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-Gly3-Val-Cit-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-164309
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBCO-PEG3-Glu-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. DBCO-PEG3-Glu-Val-Cit-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162) and can be used for synthesis of dual-drug ADC .
|
-
- HY-136098
-
|
|
ADC Linker
|
Cancer
|
|
DBCO-PEG4-acetic-Val-Cit-PAB is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-acetic-Val-Cit-PAB is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-136103
-
|
|
ADC Linker
|
Cancer
|
|
DBCO-PEG4-Propionic-Val-Cit-PAB is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-Propionic-Val-Cit-PAB is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-130923
-
|
|
ADC Linker
|
Cancer
|
|
BCN-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . BCN-PEG1-Val-Cit-PABC-OH is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-136154
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-Glu-(Boc)-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-W190943
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-130966
-
|
|
ADC Linker
|
Cancer
|
|
TCO-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . TCO-PEG1-Val-Cit-PABC-OH is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
|
-
- HY-136100
-
|
|
ADC Linker
|
Cancer
|
|
TCO-PEG1-Val-Cit-PABC-PNP is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). TCO-PEG1-Val-Cit-PABC-PNP is a click chemistry reagent, which contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups .
|
-
- HY-133459
-
|
|
ADC Linker
|
Cancer
|
|
Mal-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-140150
-
|
|
ADC Linker
PROTAC Linkers
|
Cancer
|
|
Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG3-Val-Cit-PAB-PNP is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Azido-PEG3-Val-Cit-PAB-PNP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-140149
-
|
|
ADC Linker
PROTAC Linkers
|
Cancer
|
|
Azido-PEG4-Val-Cit-PAB-OH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG4-Val-Cit-PAB-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Azido-PEG4-Val-Cit-PAB-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-131156
-
|
|
ADC Linker
|
Cancer
|
|
Mal-PEG2-Val-Cit-PABA-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-140144
-
|
|
ADC Linker
|
Cancer
|
|
Mal-PEG1-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-112100
-
|
|
PROTAC-Linker Conjugates for PAC
Estrogen Receptor/ERR
|
Cancer
|
|
MC-Val-Cit-PAB-PROTAC ERα Degrader-1 (compound LP2) consists an ADC linker and a PROTAC, whcih can be conjugated to an antibody to form PACs. MC-Val-Cit-PAB-PROTAC ERα Degrader-1 conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .
|
-
- HY-136034
-
|
|
ADC Linker
|
Cancer
|
|
Azido-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG1-Val-Cit-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-204602
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Fmoc-Val-Cit-PAB-MMAF-OtBu is a conjugate of MMAF and ADC linker, which can be coupled with the corresponding antibody to form an ADC molecule to exert anti-tumor activity .
|
-
- HY-151726
-
|
|
ADC Linker
|
Others
|
|
Azido-PEG(4)-Val-Cit-PAB-PNP is a cleavable peptide ADC linker. Azido-PEG(4)-Val-Cit-PAB-PNP is a click chemistry reagent containing an azide group. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
-
- HY-136100A
-
|
|
ADC Linker
|
Cancer
|
|
TCO-PEG1-Val-Cit-PABC-PNP TFA is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). TCO-PEG1-Val-Cit-PABC-PNP TFA is a click chemistry reagent, which contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups .
|
-
- HY-140145
-
|
|
ADC Linker
|
Cancer
|
|
Mal-PEG4-Val-Cit-PAB-PNP is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-140143
-
|
|
ADC Linker
|
Cancer
|
|
Mal-PEG4-Val-Cit-PAB-OH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-130944
-
|
|
ADC Linker
|
Cancer
|
|
Mal-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-141154
-
-
- HY-W591339
-
|
|
ADC Linker
|
Cancer
|
|
Mal-PEG8-Val-Cit-PAB-PNP is a ADC linker. Mal-VC-PAB-PNP can be used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-136108
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-Gly3-Val-Cit-PAB-PNP is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-W800847
-
|
|
ADC Linker
|
Cancer
|
|
Mal-Amide-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-141155
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable ADC linker conjugated with drug containing 4-unit PEG, which can be used for synthesizing antibody-drug conjugates (ADCs). endo-BCN-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .
|
-
- HY-W590556
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Endo-BCN-PEG4-Val-Cit-PAB-MMAF is a cleavable ADC linker conjugated with drug containing 4-unit PEG, which can be used for synthesizing antibody-drug conjugates (ADCs). endo-BCN-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .
|
-
- HY-136137
-
|
|
ADC Linker
|
Cancer
|
|
Azide-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azide-PEG1-Val-Cit-PABC-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-140148
-
|
|
ADC Linker
|
Cancer
|
|
Azido-PEG3-Val-Cit-PAB-OH is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG3-Val-Cit-PAB-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-136105
-
|
|
ADC Linker
|
Cancer
|
|
Azido-PEG1-Val-Cit-PABC-PNP is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG1-Val-Cit-PABC-PNP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-175881
-
|
|
ADC Linker
|
Cancer
|
|
3-Formyl-L-tyrosine-oxime-Val-Cit-PAPB is an ADC linker that can be used for the synthesis of the TUB-010 drug linker (HY-175884) .
|
-
- HY-157763
-
|
|
PROTAC-Linker Conjugates for PAC
Btk
|
Cancer
|
|
Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 is a cleavable linker-payload conjugate and cereblon-binding BTK bifunctional degrader. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 induces BTK degradation and exerts cytotoxic effects when delivered via CD79b monoclonal antibody. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1, when formulated as a CD79b antibody-drug conjugate, achieves sustained in vivo BTK degradation in tumor-bearing mice with reduced systemic payload exposure. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be used for the research of activated b-cell-like diffuse large b-cell lymphoma (ADC linker: (HY-130944); PROTAC: (HY-163295)) .
|
-
- HY-20336
-
|
Maleimidocaproyl-L-Valine-L-Citrulline-p-aminobenzyl alcohol p-nitrophenyl carbonate
|
ADC Linker
|
Others
Inflammation/Immunology
Cancer
|
|
Mc-Val-Cit-PABC-PNP is a cathepsin cleavable linker for antibody-drug conjugates (ADCs) which couples the antibody element to the effecting compound. Mc-Val-Cit-PABC-PNP can be used in the synthesis of ADCs .
|
-
- HY-140147
-
|
|
ADC Linker
|
Cancer
|
|
Mal-amido-PEG2-Val-Cit-PAB-PNP is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-140146
-
|
|
ADC Linker
|
Cancer
|
|
Mal-amido-PEG2-Val-Cit-PAB-OH is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-132973
-
|
|
ADC Linker
|
Cancer
|
|
MC-Val-Cit-PAB-NH-C2-NH-Boc is a cathepsin cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-178219
-
|
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE contains a linker and bioactive small molecule toxins MMAE (HY-15162). Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE can conjugate with NN2101 (HY-P991293) (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) .
|
-
- HY-151700
-
|
|
ADC Linker
|
Cancer
|
|
6-Azidohexanoyl-Val-Cit-PAB is a click chemistry reagent that can be used to synthesis vaccine . It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
-
- HY-151699
-
|
|
ADC Linker
|
Others
|
|
6-Azidohexanoyl-Val-Cit-PAB-PNP is a click chemistry reagent that can be used to synthesis It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
-
- HY-15575G
-
|
MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .
|
-
- HY-181777
-
|
|
EGFR
|
Cancer
|
|
Mal-Pip-ValCit-PAB-AZ7550 is a prodrug of EGFR inhibitor. Mal-Pip-ValCit-PAB-AZ7550 selectively binds covalently to albumin via its maleimide moiety. Mal-Pip-ValCit-PAB-AZ7550 exhibits potent in vivo anticancer activity in non-small cell lung cancer xenograft models. Mal-Pip-ValCit-PAB-AZ7550 can be used in research related to non-small cell lung cancer .
|
-
- HY-145960
-
-
- HY-131296
-
|
|
Drug Derivative
|
Inflammation/Immunology
|
|
5-A-RU-PABC-Val-Cit-Fmoc is the proagent of 5-A-RU . 5-A-RU, a precursor of bacterial Riboflavin, is a mucosal-associated invariant T (MAIT) cells activator. 5-A-RU forms potent MAIT-activating antigens via non-enzymatic reactions with small molecules, such as glyoxal and methylglyoxal, which are derived from other metabolic pathways .
|
-
- HY-145960A
-
-
- HY-15742
-
-
- HY-W008064
-
|
Fmoc-L-Citrulline
|
Amino Acid Derivatives
|
Cancer
|
|
Fmoc-Cit-OH (Fmoc-L-Citrulline) is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize a degradable ADC linker composed of a valine-citrulline (Val-Cit) motif .
|
-
- HY-177879
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
2-MSP-5-HA-Val-Cit-PAB-Exatecan (A-24) is a drug-linker conjugate for ADC. 2-MSP-5-HA-Val-Cit-PAB-Exatecan consists of Exatecan (HY-13631) and a linker. 2-MSP-5-HA-Val-Cit-PAB-Exatecan can be used for synthesis of ADCs .
|
-
- HY-185428
-
|
|
Antibody-Drug Conjugates (ADCs)
CD20
|
Cancer
|
|
TRS-005 is an anti-CD20 ADC, formed by conjugating an anti-CD20 monoclonal antibody to MMAE (HY-15162) via a Val-Cit (HY-140014) linker. TRS-005 targets CD20-positive tumor cells and delivers MMAE into cells through receptor-mediated endocytosis. TRS-005 can be used for research on relapsed/refractory B-cell non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma) .
|
-
- HY-19318A
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-D-Val-Cit-PAB is a cleavable linker for antibody-agent-conjugation (ADC) .
|
-
- HY-Z0922
-
|
|
Biochemical Assay Reagents
|
Others
|
|
6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((R)-1-(((R)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide is a biological molecule.
|
-
- HY-P99016A
-
|
|
Antibody-Drug Conjugates (ADCs)
Nectin-4
|
Cancer
|
|
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
|
-
- HY-P99016B
-
|
|
Antibody-Drug Conjugates (ADCs)
Nectin-4
|
Cancer
|
|
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
|
-
- HY-W947216
-
-
- HY-15575
-
VcMMAE
Maximum Cited Publications
92 Publications Verification
MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
|
-
- HY-141833
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Bi-Mc-VC-PAB-MMAE consists ADCs linker (Bi-Mc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE, HY-15162). Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate for ADC.
|
-
- HY-15575R
-
-
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
- HY-15575S
-
|
MC-Val-Cit-PAB-MMAE-d8; mc-vc-PAB-MMAE-d8
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
|
-
- HY-181911
-
|
|
Drug-Linker Conjugates for ADC
NAMPT
|
Neurological Disease
|
|
L2-FK866 is an ADC payload-linker conjugate (Drug-linker conjugate for ADC). L2-FK866 contains the ADC linker (Val-Cit-p-aminobenzyl) and the NAMPT inhibitor FK866 (HY-50876). L2-FK866 can be conjugated with Dinutuximab (HY-P9933) to form an ADC. L2-FK866 is applicable to neuroblastoma research .
|
-
- HY-177953
-
|
|
Drug-Linker Conjugates for ADC
c-Met/HGFR
|
Cancer
|
|
Mal-PEG2-Val-Arg-PABC-OMe-Eribulin (Compound L-1) is a drug-linker conjugate composed of O-Me Eribulin (HY-159576) and the linker Mal-PEG2-Val-Cit-PAB-OH (HY-130222). Mal-PEG2-Val-Arg-PABC-OMe-Eribulin can be used to synthesize anti-HER3/MET antibody-drug conjugates (ADCs) .
|
-
- HY-P99612
-
|
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
-
- HY-177578
-
|
|
Antibody-Drug Conjugates (ADCs)
c-Kit
Apoptosis
Microtubule/Tubulin
ERK
Akt
Caspase
|
Cancer
|
|
NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research [1][2].
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-P99016B
-
|
|
Fluorescent Dye
|
|
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
|
-
- HY-P99016A
-
|
|
Fluorescent Dye
|
|
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
|
-
- HY-15575G
-
|
MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE
|
Fluorescent Dye
|
|
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .
|
-
- HY-78738G
-
|
|
Fluorescent Dye
|
|
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
-
- HY-100374G
-
|
|
Fluorescent Dye
|
|
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
|
-
- HY-12362G
-
|
|
Fluorescent Dye
|
|
Val-cit-PAB-OH GMP is a GMP grade Val-cit-PAB-OH (HY-12362). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Val-cit-PAB-OH is a degradable ADC linker.
|
-
- HY-20336G
-
|
|
Fluorescent Dye
|
|
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-78736G
-
|
|
Fluorescent Dye
|
|
Val-Cit-PAB-OSBT GMP is a GMP grade Val-Cit-PAB-OSBT (HY-78736). Val-Cit-PAB-OSBT is a degradable ADC linker, which is composed of the polypeptide Val-Cit-PAB and OSBT groups coupled together .
|
-
- HY-19318G
-
|
|
Fluorescent Dye
|
|
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.
|
| Cat. No. |
Product Name |
Type |
-
- HY-15575G
-
|
MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE
|
Biochemical Assay Reagents
|
|
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .
|
-
- HY-78738G
-
|
|
Biochemical Assay Reagents
|
|
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
-
- HY-100374G
-
|
|
Biochemical Assay Reagents
|
|
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
|
-
- HY-12362G
-
|
|
Biochemical Assay Reagents
|
|
Val-cit-PAB-OH GMP is a GMP grade Val-cit-PAB-OH (HY-12362). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Val-cit-PAB-OH is a degradable ADC linker.
|
-
- HY-20336G
-
|
|
Biochemical Assay Reagents
|
|
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-78736G
-
|
|
Biochemical Assay Reagents
|
|
Val-Cit-PAB-OSBT GMP is a GMP grade Val-Cit-PAB-OSBT (HY-78736). Val-Cit-PAB-OSBT is a degradable ADC linker, which is composed of the polypeptide Val-Cit-PAB and OSBT groups coupled together .
|
-
- HY-19318G
-
|
|
Biochemical Assay Reagents
|
|
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-W008064
-
|
Fmoc-L-Citrulline
|
Amino Acid Derivatives
|
Cancer
|
|
Fmoc-Cit-OH (Fmoc-L-Citrulline) is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize a degradable ADC linker composed of a valine-citrulline (Val-Cit) motif .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P99016B
-
|
|
Antibody-Drug Conjugates (ADCs)
Nectin-4
|
Cancer
|
|
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
|
-
(5)
-
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
(5)
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-15575S
-
|
|
|
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-140150
-
|
|
|
Azide
PROTAC Synthesis
ADC Synthesis
|
|
Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG3-Val-Cit-PAB-PNP is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Azido-PEG3-Val-Cit-PAB-PNP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-130937
-
|
|
|
ADC Synthesis
DBCO
|
|
DBCO-Val-Cit-PABC-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Val-Cit-PABC-PNP is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-130990
-
|
|
|
DBCO
ADC Synthesis
|
|
DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-141155
-
|
|
|
BCN
ADC Synthesis
|
|
endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable ADC linker conjugated with drug containing 4-unit PEG, which can be used for synthesizing antibody-drug conjugates (ADCs). endo-BCN-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .
|
-
- HY-W190943
-
|
|
|
Azide
ADC Synthesis
|
|
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-19812
-
|
LCB14-0602
|
|
ADC Synthesis
Alkynes
|
|
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a agent-linker conjugate for ADC. Acetylene-linker-Val-Cit-PABC-MMAE is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-172287
-
|
|
|
DBCO
|
|
DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.
|
-
- HY-W591408
-
|
|
|
DBCO
|
|
DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate, which can be used for the synthesis of ADC molecules. MMAE (HY-15162) is a tubulin inhibitor, which can be used as an ADC toxin. DBCO-Val-Cit-PAB is the linker with the electrophilic group .
|
-
- HY-164309
-
|
|
|
DBCO
|
|
DBCO-PEG3-Glu-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. DBCO-PEG3-Glu-Val-Cit-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162) and can be used for synthesis of dual-drug ADC .
|
-
- HY-130923
-
|
|
|
ADC Synthesis
BCN
|
|
BCN-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . BCN-PEG1-Val-Cit-PABC-OH is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-151726
-
|
|
|
Azide
|
|
Azido-PEG(4)-Val-Cit-PAB-PNP is a cleavable peptide ADC linker. Azido-PEG(4)-Val-Cit-PAB-PNP is a click chemistry reagent containing an azide group. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
-
- HY-W190913
-
|
|
|
DBCO
|
|
DBCO-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. PNP can be substituted by amine-containing payload. DBCO enable click chemistry with azide molecules.
|
-
- HY-130936
-
|
|
|
ADC Synthesis
DBCO
|
|
DBCO-Val-Cit-PABC-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Val-Cit-PABC-OH is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-130966
-
|
|
|
TCO
ADC Synthesis
|
|
TCO-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . TCO-PEG1-Val-Cit-PABC-OH is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
|
-
- HY-140149
-
|
|
|
ADC Synthesis
PROTAC Synthesis
Azide
|
|
Azido-PEG4-Val-Cit-PAB-OH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG4-Val-Cit-PAB-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Azido-PEG4-Val-Cit-PAB-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-130935
-
|
|
|
ADC Synthesis
DBCO
|
|
DBCO-Val-Cit-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Val-Cit-OH is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-136100
-
|
|
|
ADC Synthesis
TCO
|
|
TCO-PEG1-Val-Cit-PABC-PNP is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). TCO-PEG1-Val-Cit-PABC-PNP is a click chemistry reagent, which contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups .
|
-
- HY-140148
-
|
|
|
Azide
ADC Synthesis
|
|
Azido-PEG3-Val-Cit-PAB-OH is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG3-Val-Cit-PAB-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-136105
-
|
|
|
Azide
ADC Synthesis
|
|
Azido-PEG1-Val-Cit-PABC-PNP is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG1-Val-Cit-PABC-PNP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-126676
-
|
|
|
PROTAC Synthesis
ADC Synthesis
DBCO
|
|
DBCO-(PEG2-Val-Cit-PAB)2 is a dual cleavable ADC linker for antibody-drug conjugates (ADCs). DBCO-(PEG2-Val-Cit-PAB)2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. DBCO-(PEG2-Val-Cit-PAB)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-136098
-
|
|
|
ADC Synthesis
DBCO
|
|
DBCO-PEG4-acetic-Val-Cit-PAB is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-acetic-Val-Cit-PAB is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-136103
-
|
|
|
ADC Synthesis
DBCO
|
|
DBCO-PEG4-Propionic-Val-Cit-PAB is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-Propionic-Val-Cit-PAB is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-151699
-
|
|
|
Azide
|
|
6-Azidohexanoyl-Val-Cit-PAB-PNP is a click chemistry reagent that can be used to synthesis It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
-
- HY-W800814
-
|
|
|
Azide
|
|
Azido-PEG8-Amido-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome, the ADC payload will be released only in the cell. Azido will react with DBCO, BCN or other alkyne groups through click chemistry. PEG spacer increases aqueous solubility. Reagent grade, for research purpose.
|
-
- HY-W947216
-
-
- HY-130922
-
|
|
|
BCN
ADC Synthesis
|
|
BCN-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . BCN-PEG1-Val-Cit-OH is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-130934
-
|
|
|
ADC Synthesis
TCO
|
|
TCO-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . TCO-PEG1-Val-Cit-OH is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
|
-
- HY-136034
-
|
|
|
ADC Synthesis
Azide
|
|
Azido-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG1-Val-Cit-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-136137
-
|
|
|
ADC Synthesis
Azide
|
|
Azide-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azide-PEG1-Val-Cit-PABC-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-151700
-
|
|
|
Azide
|
|
6-Azidohexanoyl-Val-Cit-PAB is a click chemistry reagent that can be used to synthesis vaccine . It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
-
- HY-W590556
-
|
|
|
BCN
|
|
Endo-BCN-PEG4-Val-Cit-PAB-MMAF is a cleavable ADC linker conjugated with drug containing 4-unit PEG, which can be used for synthesizing antibody-drug conjugates (ADCs). endo-BCN-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .
|
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-78736G
-
|
|
ADC Linker
|
Cancer
|
|
Val-Cit-PAB-OSBT GMP is a GMP grade Val-Cit-PAB-OSBT (HY-78736). Val-Cit-PAB-OSBT is a degradable ADC linker, which is composed of the polypeptide Val-Cit-PAB and OSBT groups coupled together .
|
-
-
- HY-100374G
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
|
-
-
- HY-12362G
-
|
|
ADC Linker
|
Cancer
|
|
Val-cit-PAB-OH GMP is a GMP grade Val-cit-PAB-OH (HY-12362). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Val-cit-PAB-OH is a degradable ADC linker.
|
-
-
- HY-19318G
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.
|
-
-
- HY-20336G
-
|
|
ADC Linker
|
Cancer
|
|
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-78738G
-
|
|
ADC Linker
|
Cancer
|
|
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
-
-
- HY-15575G
-
|
MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
